Biotechnological production of statins: metabolic aspects and genetic approaches.

Clicks: 355
ID: 3804
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #9 of 195 articles by views in current pharmaceutical biotechnology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 195 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Statins are a class of drugs used for people with abnormal lipid levels (hyperlipidemia) that are among the best-selling medications in the United States. Thus, the biotechnological production of these drugs is of extreme importance for the pharmaceutical industry. Herein, we provide a non-exhaustive review of fungal species used to produce statin and highlighted the major factors affecting the efficacy of this process. The current biotechnological approaches and the advances of metabolic engineer to improve statins production by fungi are also emphasised. The biotechnological production of the main statins (lovastatin, pravastatin and simvastatin) use different species of filamentous fungi, among them Aspergillus terreus. The statins production is influenced by different types of nutrients available in the medium such as the carbon and nitrogen sources, and several researches have focused their efforts to find the optimal cultivation conditions. Enzymes belonging to Lov class, play essential roles in statin production and have been targeted to genetic manipulations in order to improve the efficiency for Lovastatin and Simvastatin production. For instance, Escherichia coli strains expressing the LovD have been successfully used for lovastatin production. Other examples of include the use of iRNA targeting LovF of A. terreus. Therefore, the fungi are important allies in the fight against hyperlipidemias. Although many studies have been conducted, investigations on bioprocess optimization (using both native or genetic-modified strains) are necessary.
Reference Key
moraes-neto2019biotechnologicalcurrent Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Moraes Neto, Roberval Nascimento;Barros Gomes, Edelvio de;Weba-Soares, Lucas;Dias, Leo Ruben;Nascimento da Silva, Luís Cláudio;Mendonça de Miranda, Rita de Cassia;
Journal current pharmaceutical biotechnology
Year 2019
DOI
10.2174/1389201020666190718165746
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.